Daniels, Benjamin http://orcid.org/0000-0001-8617-6055
Kiely, Belinda E.
Tang, Monica
Tervonen, Hanna
Pearson, Sallie-Anne
Funding for this research was provided by:
National Health and Medical Research Council (1060407, CRC-P-439, 1151479)
National Breast Cancer Foundation (DS-18-01)
Translational Cancer Research Network Clinical PhD Scholarship Top-Up award (no award number)
Article History
Received: 2 December 2018
Accepted: 3 September 2019
First Online: 11 September 2019
Ethics approval and consent to participate
: Our (DHS) External Request Evaluation Committee (Approval Numbers: MI1474, MI1475, MI1477, study was approved by the NSW Population and Health Services Research Ethics Committee (Approval Number: 2010/02/213) and data access was granted by the Australian Department of Human Services (DHS) (MI5858). Individual consent for the release of these data has been waived according to the Australian Privacy Act of 1988 [CitationRef removed].
: Not applicable.
: BEK has received conference support and speaker’s honorariums from Roche and advisory board honorariums from Novartis and Teva. MT has received travel support from Roche. SAP is a member of the Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper do not represent those of the either committee. The remaining authors declare no conflicts of interest.